Transcriptomics

Dataset Information

9

Effect of Sirolimus treatment on lupus nephritis in NZB/W F1 female mice


ABSTRACT: NZB/WF1 female mice spontaneously develop autoimmune lupus nephritis. Expression profiling of kidney tissue from (a) 12 week NZB/W F1 female mice defined as asymptomatic for lupus nephritis, (b) 36 and 42 week NZB/W F1 female mice defined as diseased/symptomatic for lupus nephritis and (c) 36 and 42 week NZB/W F1 female mice that are diseased/symptomatic for lupus nephritis and treated with Sirolimus was carried out. The goal of the study was to identify genes associated with lupus nephritis and modulated by Sirolimus, an inhibitor of mTOR. In addition, lupus nephritis genes resistant to Sirolimus therapy were also identfied This series of samples comprises of kidney tissue from (a) 12 week old NZB/W F1 female mice defined as asymptomatic for lupus nephritis (N=4), (b) 36 (N=3) and 42 week (N=3) old NZB/W F1 female mice defined as diseased/symptomatic for lupus nephritis and (c) 36 (N=3)and 42 (N=3) week old NZB/W F1 female mice that are asymptomatic for lupus nephritis on treatment with Sirolimus

ORGANISM(S): Mus musculus  

SUBMITTER: Samuel J Goldman   Mark J Collins  Padmalatha S Reddy  Margot O'Toole  Stuart Murray  Padmalatha Reddy  Wei Liu  Elizabet Goad  Andrew J Dorner  Joseph P Sypek  Holly M Legault 

PROVIDER: E-GEOD-12024 | ArrayExpress | 2008-11-20

SECONDARY ACCESSION(S): GSE12024PRJNA113299

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis.

Reddy Padmalatha S PS   Legault Holly M HM   Sypek Joseph P JP   Collins Mark J MJ   Goad Elizabeth E   Goldman Samuel J SJ   Liu Wei W   Murray Stuart S   Dorner Andrew J AJ   O'Toole Margot M  

Arthritis research & therapy 20081103 6


Treatment with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be efficacious in the MRL/lpr and NZB x NZW F1 mouse models of lupus nephritis, indicating a critical role for the mTOR pathway in both models. This type of demonstration of efficacy in animal models is usually a pre-requisite for advancement into clinical development. However, efficacy in an animal model often has not translated to the desired activity in the clinic. Therefore, a more profound understa  ...[more]

Similar Datasets

2008-11-21 | GSE12024 | GEO
| GSE86425 | GEO
| GSE86424 | GEO
| PRJNA113299 | ENA
2011-12-31 | E-GEOD-27045 | ArrayExpress
2011-12-31 | GSE27045 | GEO
2012-08-01 | E-GEOD-32592 | ArrayExpress
| GSE86423 | GEO
2008-01-12 | GSE10144 | GEO
2010-05-26 | E-GEOD-10144 | ArrayExpress